Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack

NCT ID: NCT00399503

Last Updated: 2016-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-09-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the usefulness of noninvasive tests of the structure of the heart and the nervous system controlling the heart. It will assess whether combining tests that evaluate heart structure with others that measure the nervous system controlling the heart will identify most patients who develop serious heart rhythm problems after a heart attack.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background. Sudden cardiac death (SCD) kills \>450,000 North Americans each year. Patients with a history of myocardial infarction (MI) are at particular risk. Concurrent alterations in myocardial structure \& autonomic tone appear important for the development of the arrhythmias leading to SCD.

Given the grave consequences of SCD, an ideal testing procedure should identify most of those at risk (sensitive) \& correctly classify risk (accurate). Since \>90% of patients who suffer serious arrhythmias post-MI have at least mild left ventricular (LV) dysfunction (ejection fraction \[EF\] \<0.50) this is an optimal group to study.

While noninvasive tests have been developed to estimate SCD risk, prior approaches have failed to: 1) identify the majority of patients at risk for serious arrhythmias (insensitive), 2) evaluate temporal changes in parameters, 3) identify the optimal timing for risk assessment post-MI, \& 4) develop a widely-applicable screening tool. This has resulted in a failure to delivery effective therapies (e.g., defibrillator) in a cost-effective manner.

Hypotheses. Primary: Concurrent evaluation of electrical structure \& autonomic tone will accurately identify most post-MI patients at risk of serious arrhythmic events. Secondary: 1) assessment later (16 weeks) provides more prognostic information than assessment early post-MI (4 weeks), 2) a single multi-parameter test procedure can be developed, and 3) individually, repolarization alternans provides the most prognostic information.

Methods. 350 persons with a recent MI (\<31 days) \& EF \<0.50 will undergo testing early (4 weeks), intermediate (8 weeks) \& late (16 weeks) post-MI.

Four techniques assess cardiac structure (spectral T-wave alternans \[TWA\], modified moving average TWA; signal-averaged \[SA\] ECG) \& nuclear ejection fraction. Three others evaluate autonomic tone (baroreceptor sensitivity \[BRS\], heart rate variability \[HRV\], and Heart Rate Turbulence \[HRT\]).

Data Collection \& Outcomes. Patients will be recruited over 24 months \& followed biannually for four years. Committee (blinded) endpoint classification \& central laboratory data analysis will be utilized. A composite of resuscitated cardiac arrest and cardiac mortality is the primary outcome. The components (resuscitated / non-resuscitated cardiac arrest and cardiac death) are secondary outcomes.

Statistical Aspects \& Sample Size. Standard methods of description \& analysis will be used. The capacity to accurately identify most patients at risk for serious arrhythmias will be evaluated using Cox multivariate models. The primary model will include age, sex, EF at 8 wks \& important baseline medication use.

Since multivariate modeling requires lower (more sensitive) dichotomy limits the following will be used: spectral TWA positivity will be defined as a non-negative test. SA-ECG QRS width \>104 msec will be labeled as abnormal. For HRV, SDNN values \<105 msec will be considered abnormal. For BRS, values \<6.1 msec per mmHg will indicate impairment. For HRT abnormalities in T-onset \& / or T-slope will be considered abnormal. Receiver operating characteristic curves will be used to identify a cut-point for modified moving average TWA.

Assuming a 5 year 20% rate of the composite arrhythmias in patients with positive test results, we have 85% power to detect a 2.5-fold higher risk in patients with abnormalities than those without these abnormalities.

Relevance. This is the first large prospective study to evaluate the utility of concurrent structural \& autonomic tone assessment in predicting the development of serious arrhythmias after an MI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Death, Sudden, Cardiac Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spectral T Wave Alternans

Intervention Type PROCEDURE

Modified Moving Average T Wave Alternans

Intervention Type PROCEDURE

Baroreceptor Sensitivity

Intervention Type PROCEDURE

Heart Rate Variability

Intervention Type PROCEDURE

Heart Rate Turbulence

Intervention Type PROCEDURE

Deceleration Capacity

Intervention Type PROCEDURE

Signal Averaged ECG

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed MI \<31 days, based upon elevated cardiac-specific CK (total CK-MB mass \>7ng/mL or CK-MB/total CK ≥ 2.5%) or troponin-T (\> 0.1 ng/ml)144) plus
* clinical symptoms or ECG evidence of myocardial injury (ST deviation ≥ 1 mm in 2, contiguous leads or new/previously undocumented Q waves)144, \&
* left ventricular ejection fraction ≤ 0.40 within 48 hrs or ≤ 0.50 beyond 48 hrs of MI using (echocardiography, radionuclide or contrast angiography) \&
* Sinus rhythm at the time of enrollment.

Exclusion Criteria

* Geographic isolation or inability to return for follow-up,
* Comorbid illness likely to cause death within 24 months,
* Inability to complete a submaximal exercise test (e.g., urgent CABG),
* Class I indication for a defibrillator (e.g., VF or sustained VT \> 48 hours of index MI), or
* Lack of written informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role collaborator

Heart and Stroke Foundation of Canada

OTHER

Sponsor Role collaborator

Alberta Heritage Foundation for Medical Research

OTHER

Sponsor Role collaborator

GE Healthcare

INDUSTRY

Sponsor Role collaborator

Cambridge Heart Inc.

INDUSTRY

Sponsor Role collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role collaborator

University of Calgary

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Derek V Exner, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Libin Cardiovascular Institute of Alberta, University of Calgary

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Foothills Hospital

Calgary, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, Van Schaik A, Mitchell RT, Shibata MA, Gulamhussein S, McMeekin J, Tymchak W, Schnell G, Gillis AM, Sheldon RS, Fick GH, Duff HJ; REFINE Investigators. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol. 2007 Dec 11;50(24):2275-84. doi: 10.1016/j.jacc.2007.08.042. Epub 2007 Nov 26.

Reference Type RESULT
PMID: 18068035 (View on PubMed)

Slawnych MP, Nieminen T, Kahonen M, Kavanagh KM, Lehtimaki T, Ramadan D, Viik J, Aggarwal SG, Lehtinen R, Ellis L, Nikus K, Exner DV; REFINE (Risk Estimation Following Infarction Noninvasive Evaluation); FINCAVAS (Finnish Cardiovascular Study) Investigators. Post-exercise assessment of cardiac repolarization alternans in patients with coronary artery disease using the modified moving average method. J Am Coll Cardiol. 2009 Mar 31;53(13):1130-7. doi: 10.1016/j.jacc.2008.12.026.

Reference Type DERIVED
PMID: 19324258 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSFA 73-1220

Identifier Type: -

Identifier Source: secondary_id

CIHR 73-1518

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.